Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.
On October 24, 2025 the company will present three posters: Poster 12 — Acetylcholinesterase Inhibitors and Psychotropic Medication Use in ADRD; Poster 3 — Persistence of Therapy in ADRD; and Poster 4 — Evidence-Based Approaches to Switching AChEIs in Alzheimer’s Disease. Presentations include insights on cholinesterase inhibitors and ZUNVEYL (benzgalantamine) aimed at updating evidence-based guidance for clinicians treating older adults with neurodegenerative disease.
Alpha Cognition (Nasdaq: ACOG) has announced the pricing of its oversubscribed public offering of 5.6 million common shares at $6.25 per share, raising approximately $35 million in gross proceeds. The offering includes a 30-day over-allotment option for an additional 840,000 shares.
The company's total cash position is expected to reach $70 million post-closing. The proceeds will fund the commercial launch acceleration of ZUNVEYL® (Benzgalantamine), focusing on sales expansion, marketing investment, and enhancing payer coverage and reimbursement infrastructure in the Alzheimer's treatment market.
The offering, led by Titan Partners Group, is expected to close around October 2, 2025, with strong participation from both existing shareholders and a premier healthcare-dedicated investor.
Alpha Cognition (NASDAQ:ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced a proposed underwritten public offering of common shares and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to 15% additional common shares.
The net proceeds will be used to accelerate commercial launch activities, including sales expansion, marketing investment, and enhancing payer coverage infrastructure in the Alzheimer's treatment landscape. Titan Partners Group is acting as the sole bookrunner for this offering, which will be made under the company's effective S-3 shelf registration.
Alpha Cognition (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative disease treatments, has announced its upcoming participation in two major healthcare investor conferences in September 2025.
CEO Michael McFadden will present at the Cantor Global Healthcare Conference on September 5 at 7:00 a.m. ET and the H.C. Wainwright & Co. Healthcare Conference on September 9 at 2:00 p.m. ET. Presentation transcripts will be available on the company's website for 30 days following the events.
Alpha Cognition (NASDAQ:ACOG) reported Q2 2025 financial results and operational updates, highlighting the successful launch of ZUNVEYL with $2 million in net product revenues year-to-date, including $1.6 million in Q2. The company's sales team has engaged with over 3,700 healthcare professionals and generated prescriptions in more than 300 nursing homes.
The company secured its first national Medicare Part D contract without prior authorization requirements. Additionally, ACOG completed a pre-clinical Bomb Blast study for ALPHA-1062 with the U.S. Department of Defense, showing reduced neuroinflammation and neuropathology associated with blast trauma.
Financial position remains strong with $39.4 million in cash as of June 30, 2025, providing an estimated two-year runway at current utilization rates. The company reported a Q2 net loss of $10.5 million, including a $5.2 million non-cash warrant liability adjustment.
Alpha Cognition (Nasdaq: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, will release its Q2 2025 financial results on August 14, 2025 after market close.
The company will host a conference call to discuss the results, with management providing a detailed review of financial performance and operational updates. Investors can access the call through various channels, including telephone dial-in and a live audio webcast.
Alpha Cognition (Nasdaq: ACOG) announced that its partner China Medical System Holdings Limited (CMS) has received acceptance of the New Drug Application (NDA) for ZUNVEYL® (Benzgalantamine) by China's National Medical Products Administration (NMPA) for review. The application is for treating mild-to-moderate Alzheimer's dementia.
The company stands to receive regulatory and sales milestones, plus royalties upon ZUNVEYL's approval in China and other Asian territories. According to Lancet Public Health, there are approximately 7.93 million patients with mild-to-moderate Alzheimer's dementia in China, with numbers expected to rise due to aging population trends.
Alpha Cognition (Nasdaq: ACOG) announced it will present new clinical data for its Alzheimer's treatment ZUNVEYL® at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada.
The company will present three poster presentations focusing on ZUNVEYL's bioequivalence to galantamine hydrobromide in different conditions and its dose proportionality. The presentations will showcase data from studies examining doses ranging from 5 to 15 milligrams under various conditions, including fed and fasting states.
Alpha Cognition (Nasdaq: ACOG) announced positive preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), particularly focusing on blast trauma injuries relevant to military personnel. The study, supported by the US Department of Defense and conducted with VA investigators, demonstrated significant therapeutic potential.
The research revealed that ALPHA-1062 reduced three toxic forms of brain protein Tau: pTau 217 (linked to long-term cognitive decline risk), pTau-S202/T205 (present in early-stage Alzheimer's pathology), and pTau 231 (elevated in early Alzheimer's and TBI). Additionally, high-dose ALPHA-1062 showed positive effects by reducing neuroinflammation markers and increasing nerve growth factor receptor expression.
The company's next steps include completing formulation of ALPHA-1062 for sublingual administration and conducting a bridging pharmacokinetic study comparing it to ZUNVEYL® and an existing intranasal formulation.
Alpha Cognition (NASDAQ: ACOG) reported its Q1 2025 financial results, highlighting the successful launch of ZUNVEYL (benzgalantamine) in the US long-term care market on March 17, 2025. The company secured $2.6M in licensing revenues from its partnership with CMS Pharma and reported initial ZUNVEYL product revenues of $347,000.
The company's net loss decreased to $2.0M from $5.0M in the same period last year. Cash position stands at $45.5M as of March 31, 2025, providing an estimated two-year runway. The company strengthened its intellectual property portfolio with a new composition patent extending ZUNVEYL's US protection through 2044.